O	0	10	Randomized
O	11	16	Trial
O	17	19	of
B-intervention	20	30	Lisinopril
O	31	37	Versus
B-intervention	38	48	Carvedilol
O	49	51	to
O	52	59	Prevent
B-condition	60	71	Trastuzumab
I-condition	72	86	Cardiotoxicity
O	87	89	in
O	90	98	Patients
O	99	103	With
O	104	110	Breast
O	111	117	Cancer
O	117	118	.

O	119	130	Trastuzumab
O	131	133	is
O	134	140	highly
O	141	150	effective
O	151	154	for
O	155	160	human
O	161	170	epidermal
O	171	177	growth
O	178	184	factor
O	185	193	receptor
O	194	198	type
O	199	200	2
O	201	202	(
O	202	206	HER2
O	206	207	)
O	207	208	-
O	208	216	positive
O	217	223	breast
O	224	230	cancer
O	231	234	but
O	235	237	is
O	238	248	associated
O	249	253	with
O	254	255	a
O	256	263	decline
O	264	266	in
O	267	271	left
O	272	283	ventricular
O	284	292	ejection
O	293	301	fraction
O	301	302	.

O	303	306	The
O	307	314	purpose
O	315	317	of
O	318	322	this
O	323	328	study
O	329	332	was
O	333	335	to
O	336	345	determine
O	346	353	whether
O	354	365	angiotensin
O	365	366	-
O	366	376	converting
O	377	383	enzyme
O	384	394	inhibitors
O	395	397	or
O	398	402	beta
O	402	403	-
O	403	411	blockers
O	412	418	reduce
O	419	422	the
O	423	427	rate
O	428	430	of
O	431	442	trastuzumab
O	442	443	-
O	443	450	induced
O	451	465	cardiotoxicity
O	466	467	(
O	467	471	left
O	472	483	ventricular
O	484	492	ejection
O	493	501	fraction
O	502	510	decrease
O	511	512	>
O	512	514	10
O	514	515	%
O	515	516	,
O	517	519	or
O	520	521	>
O	521	522	5
O	522	523	%
O	524	526	if
O	527	532	below
O	533	535	50
O	535	536	%
O	536	537	)
O	538	541	and
O	542	547	limit
O	548	557	treatment
O	558	571	interruptions
O	571	572	.

O	573	575	In
O	576	580	this
O	581	587	double
O	587	588	-
O	588	593	blind
O	593	594	,
O	595	606	multicenter
O	606	607	,
O	608	615	placebo
O	615	616	-
O	616	626	controlled
O	627	632	trial
O	632	633	,
O	634	648	cardiotoxicity
O	649	652	and
O	653	662	treatment
O	663	676	interruptions
O	677	679	in
B-eligibility	680	688	patients
I-eligibility	689	693	with
I-eligibility	694	698	HER2
I-eligibility	698	699	-
I-eligibility	699	707	positive
I-eligibility	708	714	breast
I-eligibility	715	721	cancer
I-eligibility	722	729	treated
I-eligibility	730	734	with
I-eligibility	735	746	trastuzumab
I-eligibility	747	750	for
I-eligibility	751	753	12
I-eligibility	754	760	months
O	761	765	were
O	766	775	evaluated
O	776	780	over
O	781	782	a
O	783	784	2
O	784	785	-
O	785	789	year
O	790	796	period
O	796	797	.

O	798	806	Patients
O	807	811	were
O	812	822	stratified
O	823	825	by
O	826	839	anthracycline
O	840	843	use
O	844	847	and
O	848	852	then
O	853	863	randomized
O	864	866	to
O	867	874	receive
O	875	885	lisinopril
O	885	886	,
O	887	897	carvedilol
O	897	898	,
O	899	901	or
B-control	902	909	placebo
O	909	910	.

O	911	914	The
O	915	920	study
O	921	929	included
B-total-participants	930	933	468
O	934	939	women
O	939	940	,
O	941	944	age
B-age	945	947	51
I-age	948	949	Â±
I-age	950	952	10
I-age	952	953	.
I-age	953	954	7
I-age	955	960	years
O	960	961	.

O	962	965	For
O	966	969	the
O	970	976	entire
O	977	983	cohort
O	983	984	,
B-outcome	985	999	cardiotoxicity
O	1000	1003	was
O	1004	1014	comparable
O	1015	1017	in
O	1018	1021	the
O	1022	1023	3
O	1024	1028	arms
O	1029	1032	and
O	1033	1041	occurred
O	1042	1044	in
B-cv-bin-percent	1045	1047	32
I-cv-bin-percent	1047	1048	%
O	1049	1051	of
O	1052	1060	patients
O	1061	1063	on
O	1064	1071	placebo
O	1071	1072	,
B-iv-bin-percent	1073	1075	29
I-iv-bin-percent	1075	1076	%
O	1077	1079	on
O	1080	1090	carvedilol
O	1090	1091	,
O	1092	1095	and
B-iv-bin-percent	1096	1098	30
I-iv-bin-percent	1098	1099	%
O	1100	1102	on
O	1103	1113	lisinopril
O	1113	1114	.

O	1115	1118	For
O	1119	1127	patients
O	1128	1137	receiving
O	1138	1152	anthracyclines
O	1152	1153	,
O	1154	1157	the
B-outcome	1158	1163	event
I-outcome	1164	1169	rates
O	1170	1174	were
O	1175	1181	higher
O	1182	1184	in
O	1185	1188	the
O	1189	1196	placebo
O	1197	1202	group
O	1203	1204	(
B-cv-bin-percent	1204	1206	47
I-cv-bin-percent	1206	1207	%
O	1207	1208	)
O	1209	1213	than
O	1214	1216	in
O	1217	1220	the
O	1221	1231	lisinopril
O	1232	1233	(
B-iv-bin-percent	1233	1235	37
I-iv-bin-percent	1235	1236	%
O	1236	1237	)
O	1238	1241	and
O	1242	1245	the
O	1246	1256	carvedilol
O	1257	1258	(
B-iv-bin-percent	1258	1260	31
I-iv-bin-percent	1260	1261	%
O	1261	1262	)
O	1263	1269	groups
O	1269	1270	.

B-outcome	1271	1285	Cardiotoxicity
I-outcome	1285	1286	-
I-outcome	1286	1290	free
I-outcome	1291	1299	survival
O	1300	1303	was
O	1304	1310	longer
O	1311	1313	on
O	1314	1318	both
O	1319	1329	carvedilol
O	1330	1331	(
O	1331	1337	hazard
O	1338	1343	ratio
O	1343	1344	:
O	1345	1346	0
O	1346	1347	.
O	1347	1349	49
O	1349	1350	;
O	1351	1353	95
O	1353	1354	%
O	1355	1365	confidence
O	1366	1374	interval
O	1374	1375	:
O	1376	1377	0
O	1377	1378	.
O	1378	1380	27
O	1381	1383	to
O	1384	1385	0
O	1385	1386	.
O	1386	1388	89
O	1388	1389	;
O	1390	1391	p
O	1392	1393	=
O	1394	1395	0
O	1395	1396	.
O	1396	1399	009
O	1399	1400	)
O	1401	1404	and
O	1405	1415	lisinopril
O	1416	1417	(
O	1417	1423	hazard
O	1424	1429	ratio
O	1429	1430	:
O	1431	1432	0
O	1432	1433	.
O	1433	1435	53
O	1435	1436	;
O	1437	1439	95
O	1439	1440	%
O	1441	1451	confidence
O	1452	1460	interval
O	1460	1461	:
O	1462	1463	0
O	1463	1464	.
O	1464	1466	30
O	1467	1469	to
O	1470	1471	0
O	1471	1472	.
O	1472	1474	94
O	1474	1475	;
O	1476	1477	p
O	1478	1479	=
O	1480	1481	0
O	1481	1482	.
O	1482	1485	015
O	1485	1486	)
O	1487	1491	than
O	1492	1494	on
O	1495	1502	placebo
O	1502	1503	.

O	1504	1506	In
O	1507	1510	the
O	1511	1516	whole
O	1517	1523	cohort
O	1523	1524	,
O	1525	1527	as
O	1528	1532	well
O	1533	1535	as
O	1536	1538	in
O	1539	1542	the
O	1543	1556	anthracycline
O	1557	1560	arm
O	1560	1561	,
O	1562	1570	patients
O	1571	1573	on
O	1574	1580	active
O	1581	1588	therapy
O	1589	1593	with
O	1594	1600	either
O	1601	1612	angiotensin
O	1612	1613	-
O	1613	1623	converting
O	1624	1630	enzyme
O	1631	1640	inhibitor
O	1641	1643	or
O	1644	1648	beta
O	1648	1649	-
O	1649	1657	blockers
O	1658	1669	experienced
O	1670	1675	fewer
B-outcome	1676	1689	interruptions
O	1690	1692	in
O	1693	1704	trastuzumab
O	1705	1709	than
O	1710	1715	those
O	1716	1718	on
O	1719	1726	placebo
O	1726	1727	.

O	1728	1730	In
O	1731	1739	patients
O	1740	1744	with
O	1745	1749	HER2
O	1749	1750	-
O	1750	1758	positive
O	1759	1765	breast
O	1766	1772	cancer
O	1773	1780	treated
O	1781	1785	with
O	1786	1797	trastuzumab
O	1797	1798	,
O	1799	1803	both
O	1804	1814	lisinopril
O	1815	1818	and
O	1819	1829	carvedilol
O	1830	1839	prevented
B-outcome	1840	1854	cardiotoxicity
O	1855	1857	in
O	1858	1866	patients
O	1867	1876	receiving
O	1877	1891	anthracyclines
O	1891	1892	.

O	1893	1896	For
O	1897	1901	such
O	1902	1910	patients
O	1910	1911	,
O	1912	1922	lisinopril
O	1923	1925	or
O	1926	1936	carvedilol
O	1937	1943	should
O	1944	1946	be
O	1947	1957	considered
O	1958	1960	to
O	1961	1969	minimize
O	1970	1983	interruptions
O	1984	1986	of
O	1987	1998	trastuzumab
O	1998	1999	.

O	2000	2001	(
O	2001	2011	Lisinopril
O	2012	2014	or
O	2015	2020	Coreg
O	2021	2023	CR
O	2024	2026	in
O	2027	2035	Reducing
O	2036	2040	Side
O	2041	2048	Effects
O	2049	2051	in
O	2052	2057	Women
O	2058	2062	With
O	2063	2069	Breast
O	2070	2076	Cancer
O	2077	2086	Receiving
O	2087	2098	Trastuzumab
O	2098	2099	;
O	2100	2111	NCT01009918
O	2111	2112	)
O	2112	2113	.
